ATE117375T1 - Transduktionsveränderte fibroblasten und ihre anwendung. - Google Patents

Transduktionsveränderte fibroblasten und ihre anwendung.

Info

Publication number
ATE117375T1
ATE117375T1 AT88908611T AT88908611T ATE117375T1 AT E117375 T1 ATE117375 T1 AT E117375T1 AT 88908611 T AT88908611 T AT 88908611T AT 88908611 T AT88908611 T AT 88908611T AT E117375 T1 ATE117375 T1 AT E117375T1
Authority
AT
Austria
Prior art keywords
fibroblass
transduction
altered
application
fibroblasts
Prior art date
Application number
AT88908611T
Other languages
English (en)
Inventor
Richard C Mulligan
James M Wilson
Original Assignee
Whitehead Biomedical Inst
Hughes Howard Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22255144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE117375(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Whitehead Biomedical Inst, Hughes Howard Med Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE117375T1 publication Critical patent/ATE117375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AT88908611T 1987-09-11 1988-09-08 Transduktionsveränderte fibroblasten und ihre anwendung. ATE117375T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9607487A 1987-09-11 1987-09-11

Publications (1)

Publication Number Publication Date
ATE117375T1 true ATE117375T1 (de) 1995-02-15

Family

ID=22255144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88908611T ATE117375T1 (de) 1987-09-11 1988-09-08 Transduktionsveränderte fibroblasten und ihre anwendung.

Country Status (8)

Country Link
US (1) US5460959A (de)
EP (2) EP0633318A1 (de)
JP (1) JP3015383B2 (de)
AT (1) ATE117375T1 (de)
CA (1) CA1341311C (de)
DE (1) DE3852823T2 (de)
HK (1) HK1008049A1 (de)
WO (1) WO1989002468A1 (de)

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6645942B1 (en) 1988-04-28 2003-11-11 The Salk Institute For Biological Studies Somatic cell gene therapy
JPH04507041A (ja) * 1988-12-13 1992-12-10 アメリカ合衆国 遺伝工学により修飾された内皮細胞およびその利用方法
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1990015863A1 (en) * 1989-06-13 1990-12-27 The Board Of Directors Of The Leland Stanford Junior University Isolation growth and differentiation of human muscle cells
DE69033710T2 (de) * 1989-10-24 2001-06-13 Chiron Corp Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
ATE175442T1 (de) * 1991-11-15 1999-01-15 Univ California Therapie des zentralnervensystems mit genetisch modifizierten zellen
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
JPH07509119A (ja) * 1992-02-28 1995-10-12 ブリッグハム　アンド　ウーメンズ　ホスピタル 移植片拒絶防止のための方法および化合物
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5656605A (en) * 1994-01-26 1997-08-12 Institute Of Molecular Biology, Inc. Device to promote drug-induced nerve regeneration
DE69531712T2 (de) * 1994-04-25 2004-07-01 Japan Science And Technology Corp., Kawaguchi Hybridgel, das eine biologisch aktive Substanz sekretiert
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
GB9419048D0 (en) * 1994-09-20 1994-11-09 Watt Diana J Treatment of muscular disorders
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US5842477A (en) * 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6210664B1 (en) * 1996-04-08 2001-04-03 New York University Medical Center Method for gene transfer to the central nervous system
AU765149B2 (en) * 1996-04-08 2003-09-11 New York University Medical Center Method for gene transfer to the central nervous system
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5932779A (en) 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
CA2308511C (en) 1997-10-29 2016-01-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of transfected or transduced mammalian cells for treating bone pathologies
EP1900818A3 (de) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
JP4399112B2 (ja) 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6946445B1 (en) 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
EP1093457B8 (de) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US7576176B1 (en) 1998-05-01 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
KR20010080324A (ko) * 1998-10-26 2001-08-22 조셉 에프. 엑스. 맥과이얼 아데노신 또는 아데노신 유사체를 사용한 피부 치료방법
WO2000036118A2 (en) 1998-12-16 2000-06-22 Chiron Corporation HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU767066B2 (en) 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
EP1161528A1 (de) 1999-03-12 2001-12-12 GPC Biotech Inc. Methoden und reagentien zur identifikation von synthetischen genetischen elementen
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
CN100392082C (zh) 1999-04-30 2008-06-04 启龙股份公司 保守的奈瑟球菌抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2275559A3 (de) 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimierte Boten-RNA (mRNA)
EP2275553B1 (de) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Antigenpeptide aus Neisseria
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
ES2283340T3 (es) 1999-12-30 2007-11-01 President And Fellows Of Harvard College Metodos referentes a la modulacion de la actividad del subconjunto de celulas th2 mediante modulacion de la actividad de xbp-1.
EP1897555B1 (de) 2000-01-17 2014-07-16 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
AU2001259174A1 (en) * 2000-04-28 2001-11-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
EP1290162A4 (de) * 2000-05-17 2005-08-17 Univ Oregon Health Sciences Induktion von apoptose und hemmung des zellwachstums durch das 4.33 protein
EP2431054A3 (de) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor Delta und Ypsilon
US20020068691A1 (en) * 2000-06-21 2002-06-06 Susana Salceda Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US7232880B2 (en) * 2000-10-27 2007-06-19 Oregon Health & Science University Mutant IGFBP-3 molecules that do not bind to IGFS, but retain their ability to functionally bind IGFBP-3 receptor
NZ583028A (en) 2000-10-27 2011-10-28 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
EP1404713A4 (de) 2001-05-24 2004-09-22 Human Dna Technology Inc Neues keratinocyte growth factor 2 analogon in haarfollikeln
EP1409694A4 (de) 2001-07-05 2006-02-08 Chiron Corp Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
EP1412371B1 (de) 2001-07-12 2016-02-24 University of Massachusetts IN-VIVO-HERSTELLUNG VON KLEINEN INTERFERIERENDEN RNAs, DIE DAS ABSCHALTEN VON GENEN VERMITTELN
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
EP1542719A4 (de) 2001-12-05 2006-06-21 Baylor College Medicine Verfahren und zusammensetzungen zur steuerung der knochenbildung über modulation des sympathikotonus
EP1463520B1 (de) 2001-12-12 2008-09-03 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen chlamydia tracheomatis
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7049121B2 (en) * 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP2258724A1 (de) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
US20080213281A1 (en) * 2002-12-04 2008-09-04 Applied Molecular Evolution, Inc. C/O Eli Lilly And Company Patent Division Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents
JP5568208B2 (ja) 2003-01-14 2014-08-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌治療感作物質
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
DK1624936T3 (da) 2003-05-16 2010-03-15 Univ Laval CNS-chloridmodulering og anvendelser deraf
AU2004248136B2 (en) 2003-06-02 2011-09-15 University Of Massachusetts Methods and compositions for controlling efficacy of RNA silencing
WO2005001043A2 (en) 2003-06-02 2005-01-06 University Of Massachusetts METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
EP2508608A1 (de) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Verfahren zur Behandlung neurodegenerativer Erkrankungen
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7576052B2 (en) 2003-10-17 2009-08-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
WO2005039643A2 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
ES2638274T3 (es) 2003-11-14 2017-10-19 Children's Medical Center Corporation Ribozimas de auto-escisión y usos de éstas
EP2365077B1 (de) 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA-Agenten zum VEGF-Targeting
DK1736541T3 (da) 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
ATE430763T1 (de) 2004-03-30 2009-05-15 Nsgene As Therapeutische verwendung des wachstumsfaktors nsg33
EP1753449A4 (de) * 2004-04-30 2009-09-23 Corthera Inc Verfahren und zusammensetzungen zur steuerung des fötalen wachstums mittels relaxin-modulation
EP2287310B1 (de) 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Zusammensetzungen und Verfahren zur Verwendung von MGD-CSF zur Krankheitsbehandlung
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
EP2329714A1 (de) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Einfluss von TAJ in den neuronalen Funktionen
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
ATE510545T1 (de) 2005-11-09 2011-06-15 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
NZ568272A (en) 2005-11-18 2012-02-24 Glenmark Pharmaceuticals Sa Anti-alpha2 integrin antibodies and their uses
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2008274B1 (de) 2006-03-31 2015-05-27 Alnylam Pharmaceuticals Inc. Zusammensetzungen und verfahren zur hemmung der eg5-genexpression
US7691824B2 (en) 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
ES2392478T3 (es) 2006-05-11 2012-12-11 Alnylam Pharmaceuticals Inc. Composiciones y métodos para inhibir la expresión del gen PCSK9
CA2652770A1 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
EP2192200B1 (de) 2006-05-22 2012-10-24 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der IKK-B-Gen-Expression
ES2509878T3 (es) 2006-05-25 2014-10-20 Biogen Idec Ma Inc. Anticuerpo anti-VLA-1 para tratar accidente cerebrovascular
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2111553B1 (de) 2007-01-24 2018-09-19 Carnegie Mellon University Optische biosensoren
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
ES2596584T3 (es) 2007-07-05 2017-01-10 Arrowhead Research Corporation ARNbc para tratamiento de infecciones víricas
EP2617828B1 (de) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
WO2009079399A2 (en) * 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
CA2716793A1 (en) 2008-03-05 2009-09-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2009137613A2 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
WO2010028054A1 (en) 2008-09-02 2010-03-11 Alnylam Europe Ag. Compositions and methods for inhibiting expression of mutant egfr gene
WO2010039536A2 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
US8546554B2 (en) 2008-09-25 2013-10-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
SG10201703242XA (en) 2008-10-20 2017-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
JP5855462B2 (ja) 2008-12-10 2016-02-09 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＧＮＡＱを標的としたｄｓＲＮＡ組成物および発現を阻害するための方法
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US20120021039A1 (en) 2009-01-23 2012-01-26 Nsgene A/S Expression of neuropeptides in mammalian cells
MX2011008936A (es) 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
WO2010105311A1 (en) 2009-03-20 2010-09-23 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
EP3064595B1 (de) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Verfahren für zellproliferationsbedingte erkrankungen
KR20120089743A (ko) 2009-11-09 2012-08-13 제네포드 테라퓨틱스 에이비 생체 내에서 최적화된 뉴런 특이적 연속 도파 합성을 위한 신규한 바이러스 벡터 구성물
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
JP2013517772A (ja) 2010-01-21 2013-05-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 遺伝子発見および標的確認を補助するための状況特異的遺伝子スクリーニングプラットフォーム
US20130281510A1 (en) 2010-03-29 2013-10-24 Kumamoto University siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
EP2621512B1 (de) 2010-10-01 2016-04-06 NsGene A/S Verwendung von meteorin zur behandlung von allodynie, hyperalgesie, spontanen schmerzen und phantomschmerzen
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
EP2659271A4 (de) 2010-12-27 2015-04-08 Univ Brown Therapeutische und diagnostische verfahren mit biglycan und utrophin
WO2012094511A2 (en) 2011-01-05 2012-07-12 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
MX344807B (es) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
EP3388068A1 (de) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
AU2012306810B2 (en) 2011-09-05 2017-09-28 Hoba Therapeutics Aps Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
IN2014MN01680A (de) 2012-02-13 2015-07-03 Gamida Cell Ltd
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
DK2968424T3 (da) 2013-03-13 2020-03-30 Geneweave Biosciences Inc Ikke-replikative transduktionspartikler og transduktionspartikelbaserede reportersystemer
US20160122727A1 (en) 2013-06-13 2016-05-05 Shire Human Genetic Therapies, Inc. Messenger rna based viral production
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
ES2834402T3 (es) 2014-07-24 2021-06-17 Massachusetts Eye & Ear Infirmary Terapia génica con RPGR para retinitis pigmentosa
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
EP3204119B1 (de) 2014-10-09 2021-06-09 Dana-Farber Cancer Institute, Inc. Mehrfach-variabler il-2-dosierungsplan zur behandlung von immunerkrankungen
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
WO2016123454A1 (en) 2015-01-29 2016-08-04 Board Of Trustees Of Miching State University Cryptic polypeptides and uses thereof
EP3265568B1 (de) 2015-03-06 2020-05-06 Massachusetts Eye & Ear Infirmary Genaugmentationstherapien für hereditäre netzhautdegeneration durch mutationen im prpf31-gen
EP3265825A4 (de) 2015-03-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Pd-l2-biomarker zur vorhersage von pd-1-weg-inhibitor-reaktionen bei ösophagogastrischem krebs
EP3268025B1 (de) 2015-03-10 2020-05-06 University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
EP3294334B1 (de) 2015-05-11 2020-07-08 The Johns Hopkins University Autoimmunantikörper zur verwendung bei der hemmung des wachstums von krebszellen
EP3294332A4 (de) 2015-05-14 2018-12-26 Joslin Diabetes Center, Inc. Retinolbindendes protein 3 (rbp3) als schutzfaktor bei nicht diabetischer netzhautdegeneration
KR20180034467A (ko) 2015-08-03 2018-04-04 마이오도파 리미티드 L-dopa의 전신 합성 및 조절
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
EP3362074B1 (de) 2015-10-16 2023-08-09 President and Fellows of Harvard College Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP4310503A3 (de) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Verfahren im zusammenhang mit biologika
AU2017233055A1 (en) * 2016-03-18 2018-10-04 Intrexon Corporation Compositions and methods for treatment of type VII collagen deficiencies
CN110753755B (zh) 2016-03-21 2023-12-29 丹娜法伯癌症研究院 T细胞耗竭状态特异性基因表达调节子及其用途
US20190300864A1 (en) 2016-05-20 2019-10-03 Braingene Ab Destabilising domains for conditionally stabilising a protein
WO2018001858A1 (en) 2016-06-27 2018-01-04 University Of Copenhagen Tailored assembly of a modular bud polypeptide
US11136409B2 (en) 2016-09-20 2021-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
EP3532638A4 (de) 2016-10-31 2020-07-29 University of Massachusetts Targeting von microrna-101-3p in der krebstherapie
WO2018191599A1 (en) 2017-04-14 2018-10-18 University Of Massachusetts Brown fat-selective adipokines
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
WO2019005897A1 (en) 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
PL3658184T3 (pl) 2017-07-27 2024-02-26 Alexion Pharmaceuticals, Inc. Formulacje przeciwciała anty-C5 o wysokim stężeniu
US11008602B2 (en) 2017-12-20 2021-05-18 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
WO2019229264A1 (en) 2018-06-01 2019-12-05 Sanofi Combination therapy for treating hepatitis b virus infection
AU2019308290A1 (en) 2018-07-19 2021-02-18 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with BCMA specificity and uses thereof
JP2022505679A (ja) 2018-10-23 2022-01-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
EP3902930A1 (de) 2018-12-27 2021-11-03 F. Hoffmann-La Roche AG Nicht-replikative transduktionspartikel und transduktionspartikelbasierte reportersysteme zum nachweis von acinetobacter baumannii
US11572595B2 (en) 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
CN114174345A (zh) 2019-07-24 2022-03-11 瑞泽恩制药公司 具有mage-a4特异性的嵌合抗原受体和其用途
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
AU2020397416A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis B infection
JP2023505168A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インターフェロン会合抗原結合タンパク質及びこれらの使用
WO2021136752A1 (en) 2019-12-31 2021-07-08 F. Hoffmann-La Roche Ag Quantitative pcr screening of inducible prophage from bacterial isolates
CN115427436A (zh) 2020-01-24 2022-12-02 里珍纳龙药品有限公司 黑素瘤优先表达抗原（prame）t细胞受体及其使用方法
BR112022021450A2 (pt) 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
BR112022021871A2 (pt) 2020-05-05 2023-01-31 Regeneron Pharma Polipeptídeo car, composição, ácido nucleico, célula imune, método para tratar um tumor, e, banco de células
EP4211164A1 (de) 2020-09-14 2023-07-19 Vor Biopharma Inc. Einzeldomänenantikörper gegen cd33
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
EP4263605A2 (de) 2020-12-18 2023-10-25 Momenta Pharmaceuticals, Inc. Antikörper gegen integrin alpha 11 beta 1
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
JP2024515066A (ja) 2021-04-09 2024-04-04 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
BR112023020371A2 (pt) 2021-04-26 2024-02-06 Millennium Pharm Inc Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer
AU2022266584A1 (en) 2021-04-26 2023-10-12 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
EP4333876A1 (de) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Chimäre antigenrezeptoren mit mage-a4-spezifität und verwendungen davon
JP2024518433A (ja) 2021-05-06 2024-05-01 ホバ セラピューティクス エーピーエス 化学療法誘発性神経障害性疼痛の予防及び治療
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3220925A1 (en) 2021-06-09 2022-12-15 Kara Carter Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
TW202330612A (zh) 2021-10-20 2023-08-01 日商武田藥品工業股份有限公司 靶向ｂｃｍａ之組合物及其使用方法
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2023201238A1 (en) 2022-04-11 2023-10-19 Vor Biopharma Inc. Binding agents and methods of use thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
WO1987000201A1 (en) * 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy

Also Published As

Publication number Publication date
DE3852823T2 (de) 1995-05-24
EP0633318A1 (de) 1995-01-11
JPH03500124A (ja) 1991-01-17
CA1341311C (en) 2001-10-30
HK1008049A1 (en) 1999-04-30
DE3852823D1 (de) 1995-03-02
JP3015383B2 (ja) 2000-03-06
EP0378576A1 (de) 1990-07-25
US5460959A (en) 1995-10-24
EP0378576B1 (de) 1995-01-18
WO1989002468A1 (en) 1989-03-23

Similar Documents

Publication Publication Date Title
ATE117375T1 (de) Transduktionsveränderte fibroblasten und ihre anwendung.
HK1008400A1 (en) Genetic modification of endothelial cells
CA2095153A1 (en) Genetic modification of endothelial cells
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
IE820069L (en) Recombinant dna encoding a polypeptide
DE69323879D1 (de) Herstellung von rekombinanten, menschlichem lactoferrin
IL94361A0 (en) Polypeptides,recombinant dna molecules and method of producing a human hemoglobin like protein
AU573523B2 (en) Functional human urokinase proteins
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
ES8704976A1 (es) Metodo pra la fabricacion de un polipeptido firiologicamente activo en el hombre.
DE3882593D1 (de) Polypeptid und dessen herstellung.
ATE391175T1 (de) Multidrug resistenz gen
EP0147178A3 (en) Expression plasmids for improved production of heterologous protein in bacteria
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
DE68923496D1 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.
DE3890677T1 (de) Biologische materialien, verfahren zur herstellung biologischer materialien und zur verwendung dieser materialien bei der therapie
ATE84315T1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked